Ubrogepant: First Approval

Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in...

Descripción completa

Detalles Bibliográficos
Autor principal: Scott, Lesley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062659/
https://www.ncbi.nlm.nih.gov/pubmed/32020557
http://dx.doi.org/10.1007/s40265-020-01264-5
_version_ 1783504551970603008
author Scott, Lesley J.
author_facet Scott, Lesley J.
author_sort Scott, Lesley J.
collection PubMed
description Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults. This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.
format Online
Article
Text
id pubmed-7062659
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-70626592020-03-23 Ubrogepant: First Approval Scott, Lesley J. Drugs AdisInsight Report Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults. This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults. Springer International Publishing 2020-02-05 2020 /pmc/articles/PMC7062659/ /pubmed/32020557 http://dx.doi.org/10.1007/s40265-020-01264-5 Text en © Springer Nature 2020, corrected publication 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made.
spellingShingle AdisInsight Report
Scott, Lesley J.
Ubrogepant: First Approval
title Ubrogepant: First Approval
title_full Ubrogepant: First Approval
title_fullStr Ubrogepant: First Approval
title_full_unstemmed Ubrogepant: First Approval
title_short Ubrogepant: First Approval
title_sort ubrogepant: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062659/
https://www.ncbi.nlm.nih.gov/pubmed/32020557
http://dx.doi.org/10.1007/s40265-020-01264-5
work_keys_str_mv AT scottlesleyj ubrogepantfirstapproval

Ejemplares similares